Immunity Clinical Trials

27 recruitingLast updated: May 13, 2026

There are 27 actively recruiting immunity clinical trials across 29 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 4. Top locations include Milan, Milano, Italy, Moscow, Russia, Bern, Switzerland. Updated daily from ClinicalTrials.gov.


Immunity Trials at a Glance

27 actively recruiting trials for immunity are listed on ClinicalTrialsFinder across 6 cities in 29 countries. The largest study group is Not Applicable with 9 trials, with the heaviest enrollment activity in Milan, Moscow, and Bern. Lead sponsors running immunity studies include National Institute of Allergy and Infectious Diseases (NIAID), Scientific Institute San Raffaele, and Centre Hospitalier Régional d'Orléans.

Browse immunity trials by phase

Treatments under study

About Immunity Clinical Trials

Looking for clinical trials for Immunity? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immunity trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immunity clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 27 trials

Recruiting

Characterization of Human Immune Signatures to Zoonotic Virus Exposure in Cambodia

Immunity, Humoral
National Institute of Allergy and Infectious Diseases (NIAID)400 enrolled5 locationsNCT06680843
Recruiting
Phase 2

Improving Vaccine Protection for Older Adults

Healthy AdultImmune System Responses and Trained Immunity After AS01 Administration
Singapore General Hospital40 enrolled1 locationNCT07527247
Recruiting

NIAID Centralized Sequencing Protocol

autoimmunityPrimary ImmunodeficiencyAtopy+1 more
National Institute of Allergy and Infectious Diseases (NIAID)20,000 enrolled2 locationsNCT03206099
Recruiting

VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older

Immunity, MucosalImmune System ProcessesBlood Specimen Collection
National Institute of Allergy and Infectious Diseases (NIAID)500 enrolled1 locationNCT01132859
Recruiting

Understanding Immunity to the Flu Vaccine in COVID-19 Patients

ImmunityCorona Virus InfectionFlu Vaccine
Stanford University230 enrolled1 locationNCT04579588
Recruiting
Phase 4

Secukinumab Open Label Roll-over Extension Protocol

Autoimmunity, Inflammation
Novartis Pharmaceuticals1,000 enrolled167 locationsNCT04638647
Recruiting
Phase 2

This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction

Acute Lung Injury(ALI)Natural Killer Cell Mediated ImmunityPrimary Graft Dysfunction+1 more
University of California, San Francisco120 enrolled1 locationNCT06853223
Recruiting

Autoimmunity After Checkpoint Blockade

autoimmunityCancerOncology+1 more
Abramson Cancer Center at Penn Medicine600 enrolled1 locationNCT04119713
Recruiting
Not Applicable

Effects of Bacillus Coagulans SNZ 1969 on Immune Health in Healthy School-aged Children

Immunity
Sanzyme Biologics Private Limited100 enrolled1 locationNCT07341750
Recruiting
Not Applicable

Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis

Allergic diseaseAtopic Dermatitis (AD)Autoantibody+4 more
Universitair Ziekenhuis Brussel500 enrolled1 locationNCT07316465
Recruiting
Not Applicable

Neutralizing Power of Serum Antibodies - 2

COVID-19VaccinationMucosal Immunity+3 more
Centre Hospitalier Régional d'Orléans30 enrolled1 locationNCT07085611
Recruiting
Not Applicable

The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients

Hematopoietic Cell TransplantCytomegalovirus Cell Mediated Immunity
M.D. Anderson Cancer Center105 enrolled1 locationNCT06639854
Recruiting

Early Life Malnutrition, Environmental Enteric Dysfunction and Microbiome Trajectories

Environmental Enteric DysfunctionMalnutrition in ChildrenMalnutrition (Calorie)+10 more
University of Zimbabwe368 enrolled1 locationNCT07195006
Recruiting
Not Applicable

Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Malignant Tumor

Tumor Immunity
Peking Union Medical College Hospital50 enrolled1 locationNCT06844110
Recruiting
Phase 1

First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RB201 in Healthy Adult Subjects

autoimmunity
Rarefied Biosciences Australia PTY LTD88 enrolled1 locationACTRN12625000694415
Recruiting
Not Applicable

Autoimmune Endocrine Disease Related Antibodies Before the Start of Immune Checkpoint Inhibitor Therapy

autoimmunity
Laura ICONARU500 enrolled3 locationsNCT06993727
Recruiting

To Evaluate Mucosal and Systematic Immune Response to Acute Respiratory Tract Infections of South African Children

Mucosal ImmunityRespiratory Tract Infections (RTI)
Desmond Tutu TB Centre250 enrolled2 locationsNCT06902194
Recruiting

Immunodysregulation As an Expression of Underlying Inborn Errors of Immunity: Implementation of Diagnostics and Management of Pediatric and Adult Patients with Immune System Disorders

Inborn Errors of Immunity
IRCCS Azienda Ospedaliero-Universitaria di Bologna400 enrolled1 locationNCT06773546
Recruiting
Not Applicable

Effects of LP28 on Immunity Enhancement in the Elderly

ImmunityProbioticCommon cold
Synbio Tech Inc.100 enrolled2 locationsNCT06724185
Recruiting
Not Applicable

Gfree - For Improved Blood Sugar and Reduced Inflammation.

autoimmunityMetabolic DiseaseDiabetes+1 more
Göteborg University60 enrolled2 locationsNCT05894746